A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: A prospective non-comparative pilot study

Journal of Chemotherapy

Volumn 23, Issue 6, 2011, Pages 350-353

  KolumbicLakos A ^a   Skerk V ^b   Malekovic G ^a   Dujnic Spoljarevic T ^a   Kovacic D ^a   Pasini, M ^b   Markotic A ^b   Magri, V ^c   Perletti, G ^d  

^a Pliva Croatia Ltd   (Croatia)

^b Croatia   (Croatia)

^c PARKINSON INSTITUTE   (Italy)

^d Department of Biomedical InfjEnv/Comm Sciences   (Italy)

Author keywords

Azithromycin; Chronic bacterial prostatitis; Chronic pelvic pain syndrome; Chronic prostatitis; Ciprofloxacin; Fluoroquinolone; Genitourinary infections; Macrolide; NIH CPSI

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; CHRONIC PROSTATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE CONTROL; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MALE; MICTURITION; OPEN STUDY; PAIN; PATHOGEN LOAD; PILOT STUDY; PROSPECTIVE STUDY; PROSTATE SECRETION; RECURRENT DISEASE; SCORING SYSTEM; URINALYSIS; CLINICAL TRIAL; DRUG COMBINATION; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; PROSTATITIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PROSTATITIS; RECURRENCE;

EID: 84864955844     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.6.350     Document Type: Article

References (31)

1. Wenninger K, Heiman JR, Rothman I, Berghuis JP, Berger RE. Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol 1996; 155 (3): 965-968.
2. Krieger IN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236-237.
3. Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Exp opin pharmacother 2007;8(11):1667-1674.
4. Magri V, Perletti G, Bartoletti R, Cai T, Emelyanova I, Mehik A, et al. Critical issues in chronic prostatitis. Arch Ital Urol Andro12010; 82 (2): 75-82.
5. European Association of Urology Urological Infections Guidelines: http://www.uroweb.org/gls/pdf/15_UrologicaUnfections.pdf.
6. Wagenlehner FM, Naber KG, Bschleipfer T, Brähler E, Weidner W. Prostatitis and male pelvic pain syndrome: diagnosis and treatment. Dtsch Arztebiint 2009; 106 (11): 175-183.
7. Naber KG, European Lomefloxacin Prostatitis Study Group. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2002; 20 (1): 18-27.
8. Paglia M, Peterson J, Fisher AC, Qin Z, Nicholson SC, Kahn JB. Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. Curr Med Res Opin 2010; 26 (6): 1433-1441.
9. Magri V, Montanari E, Škerk V, Markotic A, Marras E, Restelli A, et al. Ruoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Androl 2011, in press, doi: 10.1038/aja.2011.36.
10. Magri V, Trinchieri A, Pozzi G, Restelli A, Garlaschi MC, Torresani E, et al. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob Agents 2007; 29 (5): 549-556.
11. Magri V, Trinchieri A, Ceriani I, Marras E, Perletti G. Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome. Arch Ital Urol Androl 2007; 79 (2): 93-98.
12. Magri V, Trinchieri A, Montanari E, Del Nero A, Mangiarotti B, Zirpoli P, et al. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. Arch Ital Urol Andro1 2007; 79 (2): 84-92.
13. Magri V, Marras E, Škerk V, Markotić A, Restelli A, Garlaschi MC, Perletti G. Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolonemacrolide combination. Andrologia 2010; 42 (6): 366-375.
14. McNaughton Collins M, Pontari MA, O'Leary MP, Calhoun EA, Santanna J, Landis JR, et al. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med 2001; 16 (10): 656-662.
15. Stamey TA. Prostatitis. J R Soc Med 1981; 74: 22-40.
16. Propert KJ, Litwin MS, Wang Y, Alexander RB, Calhoun E, Nickel JC, et al. Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 2006; 15 (2): 299-305.
17. Faul F, Erdfelder E, Buchner A, Lang AG Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Meth 2009; 41: 1149-1160.
18. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Meth 2007; 39: 175-191.
19. Mazzoli S. Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications. FEMS Immunol Med Microbiol 2010; 59 (3): 337-344.
20. Čulić O, Eraković V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-229.
21. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opinion Infect Dis 2005; 18: 125-131.
22. Tateda K, Ishii Y, Kimura S, Horikawa M, Miyairi S, Yamaguchi K. Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery? J Infect Chemother 2007; 13: 357-367.
23. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-615.
24. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008;31 (1): 12-20.
25. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54 (1): 21-28.
26. Čulić O, Eraković V, Čepelak I, Barišić K, Brajša K, Ferenčić Ž, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450: 277-289.
27. Silva MT. Macrophage phagocytosis of neutrophils at inflammatory/infectious foci: a cooperative mechanism in the control of infection and infectious inflammation. J Leuk Bioi 2011; 89: 675-683.
28. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother 2005; 49 (12): 5013-5017.
29. Technical document on azithromycin (Teva Parenteral Medicines, Inc) NIH DAILYMED Archive, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=Oe76db5f-3f27-4c92-b270-ff4671b77a7a.
30. Nightingaie CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997; 16 (4): 438-443.
31. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001; 18: S17-S23.